Algorithm to identify non-alcoholic steatohepatitis (NASH) patients with a NAS≥4 and F≥2: algorithm derived in an American screening cohort and validation in a British non-alcoholic fatty liver disease (NAFLD) cohort- Celine Fournier

International Workshop on NASH Biomarkers 2018

Study design to validate biomarkers of therapeutic response for pre-cirrhotic NASH- Brent Tetri, MD

International Workshop on NASH Biomarkers 2018

Study design to validate biomarkers of therapeutic response in cirrhosis due to NASH- Detlef Schuppan, MD, PhD

International Workshop on NASH Biomarkers 2018

Defining therapeutic response in precirrhotic and cirrhotic NASH- Manal Abdelmalek , MD

International Workshop on NASH Biomarkers 2018

The clinical need for integrated assessment of NASH diabetes and heart disease- Arun Sanyal, MD, MBBS

International Workshop on NASH Biomarkers 2018

Use of plasma PRO-C3, PRO-C5, and PRO-C6 for the diagnosis and follow-up of fibrosis stage in patients with nonalcoholic fatty liver disease (NAFLD)- iana Leeming

International Workshop on NASH Biomarkers 2018

Neoepitope fragments of extracellular matrix as markers of fibrosis in chronic liver disease: Insights into clinical and preclinical utilization for unfolding disease pathogenesis - Diana Leeming, PhD

International Workshop on NASH Biomarkers 2018

Feasibility of Using Deep-learning-based Techniques for Liver Couinaud Segmentation and Proton Density Fat Fraction (PDFF) Estimation- Hashem Almahmoud

International Workshop on NASH Biomarkers 2018

Repeatability and Reproducibility of Multiparametric Magnetic Resonance Imaging of the Liver- Andrea Dennis

International Workshop on NASH Biomarkers 2018

FDA perspective on parallel review (Not available)- Rochelle Fink, MD, JD

International Workshop on NASH Biomarkers 2018

International Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018

HBV: diagnostics, management and screening- Marion Peters, MD

International Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018

Liver care in HIV - management of abnormal LFTs- Juan Berenguer, MD, PhD

International Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018

HCV in 2018- Jürgen Rockstroh, MD

International Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018

NAFLD: diagnostics, management and screening- Juan Macías, MD, PhD

International Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018

Fibrosis Markers and Cirrhosis management in HIV patients | Marion Peters, MD

International Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018

Response to Sofosbuvir/Ledipasvir for 8 or 12 Weeks in HCV-Monoinfected and HIV/HCV-Coinfected Patients in Clinical Practice | Anaïs Corma

International Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018

Real-life Results of Grazoprevir/Elbasvir in HCV-Infected PWID: The Zepalive Studi | Juan Macías

International Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018

Baseline Resistance-Guided Therapy Does Not Enhance the Response to Interferon-Free Treatment of HCV Infection in Real Life | Luis M. Real

International Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018

HCV care after cure- Raffaele Bruno, MD

International Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018

A Comparison of Single and Multiple Tablet Regiments for the Treatment of HCV Infection Among HIV Co-Infected Individuals | Astou Thiam

International Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018

Long-Term Changes of Liver Stiffness After the Use of All Oral DAA Regimens | Nicolás Merchante

International Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018

Follow-Up of Sustained Virologic Responders with Hepatitis C/HIV Coinfection and Advanced Liver Disease | C. Soeiro

International Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018

HBV managment in HIV patients - Karine Lacombe, MD, PhD

International Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018